AlphAIalphai — Financial news for AI agents
MarketBeatAPR 233 min read$CARE

Carter Bankshares (NASDAQ:CARE) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS

Carter Bankshares (NASDAQ:CARE) reported its quarterly earnings, with an EPS of $0.40, missing the consensus estimate of $0.49 by $0.09. Despite the earnings miss, the company's revenue of $106.91 million significantly exceeded analysts' expectations of $42.47 million. Analysts have maintained a "Buy" rating for the stock, with institutional investors increasing their stakes, reflecting continued confidence in the company.

Original reporting
MarketBeat · MarketBeat
Published Apr 23, 2026, 4:13 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Apr 23, 2026, 5:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Carter Bankshares (NASDAQ:CARE) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS — source image
Source · MarketBeat
Decision brief

The 30-second read

$CARENeutralMed
01

Why it matters

The earnings miss may temporarily dampen investor sentiment, but revenue beat and maintained buy ratings suggest resilience.

02

Market read

The news is highly relevant for investors holding or considering Carter Bankshares stock, especially in the short term.

03

What to watch

Potential macroeconomic influences or upcoming regulatory changes that could impact the banking sector.

Timing: Immediate, as earnings reports influence short-term trading decisions.

Background

Carter Bankshares is a regional bank with a focus on community banking services. Earnings reports are critical indicators of financial health and investor confidence.

Company-level read

Ticker impact

$CARENeutralMedium confidence
Context

The news pertains directly to Carter Bankshares, making it highly relevant for trading decisions.

Expected impact

Potential short-term decline followed by stabilization or slight rebound; long-term outlook remains cautiously optimistic.

Evidence & confidence

The earnings miss could negatively influence the stock temporarily, but strong revenue and positive analyst sentiment mitigate downside risks. Technical indicators and market sentiment are not provided, limiting precise prediction.

Market effects

Sector

The financial sector may experience slight negative sentiment due to earnings miss, but strong revenue figures could offset concerns.

Regional

Limited regional impact; specific to Carter Bankshares and its local markets.

Global

Negligible; the news is company-specific within the U.S. banking sector.

Counterpoint

What could challenge this read

The earnings miss could signal underlying issues not reflected in revenue, warranting caution before increasing exposure.

Key entities

  • Company
    Carter Bankshares

    A regional bank listed on NASDAQ, providing banking services.

  • Source
    MarketBeat

    Financial news and analysis provider.

Read at source← All news

Related articles

JUL 23
$CAREMed

Carter Bankshares, Inc. (CARE): Results of Operations and Financial Condition

Carter Bankshares, Inc. (CARE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 care-2q26_ex991xer.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE – July 23, 2026 Carter Bankshares, Inc. Announces Second Quarter 2026 Financial Results Martinsville, VA, July 23, 2026 – Carter Bankshares, Inc. (the “Company”) (NASDAQ:CARE), the holding compan

SEC EDGAR 8-K6 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min
SEP 8
$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.

yahoo.com2 min
SEP 8
$BKRMed

Baker Hughes (BKR) Lands Multi-Year Contract with Pakistan’s OGDC

Baker Hughes (BKR) secured a multi-year contract with Pakistan's OGDC to enhance production from mature oil and gas fields. The deal involves assessing 120 wells and providing tailored redevelopment plans. Baker Hughes aims to use AI and other technologies to improve flow assurance and restore production. The contract aligns with Baker Hughes' strategy to diversify revenue and reduce reliance on short-term drilling cycles, as evidenced by a 49% YoY increase in orders to $10.5 billion in Q2. Howe

yahoo.com3 min
SEP 7
$AAPLMed

Tim Cook Delivered a 2,720% Total Return Over 15 Years. Here's Whether John Ternus Can Do the Same for Apple Investors.

Tim Cook stepped down as Apple CEO after 15 years, delivering 2,720% total returns. New CEO John Ternus faces challenges, including margin pressure from rising memory costs. Apple is set to launch new iPhone models this week. iPhone sales grew over 20% in recent quarters, but management expects slower growth. Apple stock fell on margin concerns despite briefly surpassing $5 trillion.

aol.com3 min